
|Videos|July 28, 2015
Phase III SQUIRE Trial in Patients With NSCLC Treated With Necitumumab
Author(s)Martin Reck, MD, PhD
Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial in patients with non-small cell lung cancer (NSCLC) treated with necitumumab.
Advertisement
Reck says the rash was the only major adverse event observed, but it is easily manageable. Doses can be modified and topical treatments can be used.
Reck and his team are pleased with the results and improvements of the trial, and they believe it has presented a crucial new option for the treatment paradigm.
Martin Reck, MD, PhD, Head of Thoracic Oncology, Hospital Grosshansdorf, discusses the phase III SQUIRE trial, which investigated patients with non-small cell lung cancer (NSCLC) treated with necitumumab.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































